Trump Psychedelics Executive Order

The order directs federal agencies to loosen restrictions on clinical trials for substances that show promise in treating mental health conditions such as PTSD and depression.

FDA Commissioner Dr. Marty Makary hailed the decision as a 'historic moment' that could revolutionize psychiatric care.

Investors have responded enthusiastically, with shares of firms like Compass Pathways and Atai Life Sciences spiking by over 30%.

While some medical experts remain cautious, the administration argues that the 'Right to Try' should be expanded to include these innovative treatments for veterans and others in need.